Targeted exercise to reduce risk of fracture in postmenopausal women with low bone mass who may or may not be on antiresorptive bone medication: The MEDEX-OP trial
- Conditions
- OsteopeniaOsteoporosisMusculoskeletal - OsteoporosisPublic Health - Health service researchInjuries and Accidents - FracturesMusculoskeletal - Osteoarthritis
- Registration Number
- ACTRN12617001511325
- Lead Sponsor
- Griffith University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 116
Postmenopausal women (>=5 years)
- Low bone mass (BMD > 1 SD below age-matched mean)
- Community ambulant without walking aid
- Good general health
- Taking antiresorptive agents (bisphosphonate or denosumab) for at least 12 months OR not taking bone medication and not intending to change this choice for the study period of 8 months
- Lower limb joint injury or surgery
- Recent fracture or acute moderate to severe back pain (previous 6 months)
- Malignancy or currently receiving chemotherapy or radiation therapy
- Cognitive impairment
- Contraindications for participating in heavy physical activity;
- Conditions known to influence bone health (e.g. thyrotoxicosis or hyperparathyroidism, Paget’s disease, renal disease, diabetes, immobility)
- Taking medications known to negatively influence bone health (e.g. prolonged use of corticosteroids, thyroxine, thiazides or antiretroviral agents).
- Medical conditions that would prevent completion of either of the two exercise programs (e.g. uncontrolled cardiovascular disease, nerve disorder, spinal cord injuries)
- Lifestyle choices that prevent adherence to either of the two exercise programs for the intervention duration (e.g. longer than 3 week planned holiday in the next 8 months, etc.)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method